- Cyclo-oxygenase-2 (COX-2) inhibitors are associated with fewer gastrointestinal (GI) side effects because COX-1 inhibition decreases the protective mucus of the GI tract
Celecoxib is a COX-2 selective inhibitor. COX-1 targets the protective mucosa of the GI tract. Selective COX-2 inhibitors minimize gastrointestinal side effects by avoiding inhibition of COX-1.
- Nonselective cyclo-oxygenase (COX) inhibitors have a lower risk of cardiovascular side effects
Certain selective COX-2 inhibitors were associated with unacceptably high cardiovascular side effects and were removed from the market. Celecoxib is a selective COX-2 inhibitor.
- Cyclo-oxygenase-2 (COX-2) inhibitors preferentially target the COX isoform that is responsible for protecting the gastrointestinal (GI) tract
COX-1 is associated with the protective GI tract mucosa. COX-2 inhibitors selectively target the inflammatory pathway.
- Cyclo-oxygenase-1 (COX-1) inhibitors have been associated with an unacceptably high risk of cardiovascular events
COX-2 inhibitors have been associated with an unacceptably high risk of cardiovascular events.